434 related articles for article (PubMed ID: 30153975)
21. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
22. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E;
Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633
[TBL] [Abstract][Full Text] [Related]
23. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.
Zielinski C; Lang I; Beslija S; Kahan Z; Inbar MJ; Stemmer SM; Anghel R; Vrbanec D; Messinger D; Brodowicz T
Br J Cancer; 2016 Jan; 114(2):163-70. PubMed ID: 26657657
[TBL] [Abstract][Full Text] [Related]
24. Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer.
Petrioli R; Francini E; Cherri S; Marrelli D; Rovello F; Fiaschi AI; Miano ST; Savelli V; Calomino N; Farsi M; Vernillo R; Francini G
Anticancer Drugs; 2020 Mar; 31(3):292-297. PubMed ID: 31850915
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
[TBL] [Abstract][Full Text] [Related]
26. Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D; de Groot JW; Los M; Boers JE; Beerepoot LV; Polee MB; Beeker A; Portielje JE; Goey SH; de Jong RS; Vanhoutvin SA; Kuiper M; Sikorska K; Pluim D; Beijnen JH; Schellens JH; Grootscholten C; Tesselaar ME; Cats A
Cancer; 2016 May; 122(9):1434-43. PubMed ID: 26970343
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
28. Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Ferrero JM; Hardy-Bessard AC; Capitain O; Lortholary A; Salles B; Follana P; Herve R; Deblock M; Dauba J; Atlassi M; Largillier R
Cancer; 2016 Oct; 122(20):3119-3126. PubMed ID: 27412268
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
Muñoz A; Pericay C; García-Girón C; Alonso V; Dueñas R; Cirera L; Rivera F; Falcó E; Bustos IA; Salud A
Oncol Res; 2013; 21(4):181-91. PubMed ID: 24762224
[TBL] [Abstract][Full Text] [Related]
32. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial.
Noepel-Duennebacke S; Arnold D; Hertel J; Tannapfel A; Hinke A; Hegewisch-Becker S; Reinacher-Schick A
Clin Colorectal Cancer; 2018 Dec; 17(4):e733-e739. PubMed ID: 30145148
[TBL] [Abstract][Full Text] [Related]
33. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
[TBL] [Abstract][Full Text] [Related]
34. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
[TBL] [Abstract][Full Text] [Related]
37. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
Rosati G; Avallone A; Aprile G; Butera A; Reggiardo G; Bilancia D
Cancer Chemother Pharmacol; 2013 Jan; 71(1):257-64. PubMed ID: 23100174
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Vamvakas L; Matikas A; Karampeazis A; Hatzidaki D; Kakolyris S; Christophylakis C; Boukovinas I; Polyzos A; Georgoulias V; Souglakos J
BMC Cancer; 2014 Apr; 14():277. PubMed ID: 24755296
[TBL] [Abstract][Full Text] [Related]
40. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]